Registered title, quoted from ClinicalTrials.gov
Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma
An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Ruijin Hospital; 5 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 6
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Lead sponsorRuijin Hospital上海交通大学医学院附属瑞金医院ShanghaiHospital page
- Study siteBeijing Tiantan Hospital首都医科大学附属北京天坛医院BeijingHospital page
- Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
- Study siteSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page
- Study siteTongji Hospital华中科技大学同济医学院附属同济医院WuhanHospital page
- Study siteXuanwu Hospital首都医科大学宣武医院BeijingHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06876688, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Prior chimeric antigen receptor cellular immunotherapy targeting cd19
Exclusion criterion 2
Eastern Cooperative Oncology Group (ECOG) score of 0-2;
Inclusion criterion 3
Neutrophil count (anc) ≥1.0 x 109/L;
Inclusion criterion 7
Hemoglobin ≥ 8.0 g/dl;
Inclusion criterion 8
Platelet count ≥ 50 x 109/L;
Inclusion criterion 9
Total bilirubin ≤ 1.5 × upper limit of normal (ULN)
Inclusion criterion 10
Alanine aminotransferase/aspartate aminotransferase (ALT/AST) ≤ 2.5 x ULN or ≤ 5 x ULN (in the presence of hepatic invasion);
Inclusion criterion 11
Creatinine clearance ≥40mL/min
Inclusion criterion 12
Lipase ≤ 1.5 x ULN
Inclusion criterion 13
Known human immunodeficiency virus (hiv) infection or positive immunoassay;
Exclusion criterion 3
Other malignant tumors presently or within 3 years prior to enrollment
Exclusion criterion 9
Pregnant or lactating patients;
Exclusion criterion 11
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06876688, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age greater than or equal to 18 years old, male or female;
- Relapsed or refractory CNS-involved large b-cell lymphoma after at least first-line therapy, with an efficacy assessment of CR or PR after salvage therapy, and current stable efficacy status;
- Eastern Cooperative Oncology Group (ECOG) score of 0-2;
- Have a life expectancy of ≥ 12 weeks
- Use contraception
- Have adequate bone marrow and organ function:
- Neutrophil count (anc) ≥1.0 x 109/L;
- Hemoglobin ≥ 8.0 g/dl;
- Platelet count ≥ 50 x 109/L;
- Total bilirubin ≤ 1.5 × upper limit of normal (ULN)
- Alanine aminotransferase/aspartate aminotransferase (ALT/AST) ≤ 2.5 x ULN or ≤ 5 x ULN (in the presence of hepatic invasion);
- Creatinine clearance ≥40mL/min
- Lipase ≤ 1.5 x ULN
Exclusion Criteria:
- Severe active central nervous system symptoms
- Prior chimeric antigen receptor cellular immunotherapy targeting cd19
- Known human immunodeficiency virus (hiv) infection or positive immunoassay;
- Live vaccination within 30 days prior to study drug administration;
- Active autoimmune disease requiring systemic therapy in the last 12 months
- Allergy to the study drug or history of severe allergic reactions
- Potential risk of malignant cardiac arrhythmia
- History of stroke or intracranial hemorrhage within 3 months prior to the date of administration of study medication
- Other malignant tumors presently or within 3 years prior to enrollment
- Conditions that, in the judgment of the investigator, would interfere with full participation in the study; pose a significant risk to the subject; or interfere with the interpretation of the study data
- Pregnant or lactating patients;
Quoted from ClinicalTrials.gov, NCT06876688, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06876688, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.